KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Liabilities and Shareholders Equity (2016 - 2025)

Xenon Pharmaceuticals (XENE) has disclosed Liabilities and Shareholders Equity for 13 consecutive years, with $633.2 million as the latest value for Q4 2025.

  • Quarterly Liabilities and Shareholders Equity fell 20.67% to $633.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.7 billion through Dec 2025, down 22.65% year-over-year, with the annual reading at $633.2 million for FY2025, 20.67% down from the prior year.
  • Liabilities and Shareholders Equity for Q4 2025 was $633.2 million at Xenon Pharmaceuticals, up from $607.8 million in the prior quarter.
  • The five-year high for Liabilities and Shareholders Equity was $964.8 million in Q4 2023, with the low at $264.4 million in Q3 2021.
  • Average Liabilities and Shareholders Equity over 5 years is $671.7 million, with a median of $702.4 million recorded in 2023.
  • The sharpest move saw Liabilities and Shareholders Equity skyrocketed 202.35% in 2021, then decreased 27.28% in 2025.
  • Over 5 years, Liabilities and Shareholders Equity stood at $572.0 million in 2021, then soared by 31.84% to $754.1 million in 2022, then grew by 27.93% to $964.8 million in 2023, then dropped by 17.27% to $798.1 million in 2024, then decreased by 20.67% to $633.2 million in 2025.
  • According to Business Quant data, Liabilities and Shareholders Equity over the past three periods came in at $633.2 million, $607.8 million, and $674.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.